Codagenix, Inc
8
0
1
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
12.5%
1 terminated/withdrawn out of 8 trials
85.7%
-0.8% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
Role: lead
Intramuscular CodaVax-H1N1 in Healthy Adults
Role: lead
A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
Role: lead
Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19
Role: lead
Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19
Role: lead
Safety and Immunogenicity of a Live-attenuated Vaccine Against Respiratory Syncytial Virus in Elderly Volunteers
Role: lead
Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray
Role: lead
Safety Study of Live Attenuated Influenza Vaccine, CodaVax
Role: lead
All 8 trials loaded